As­traZeneca un­veils plans for R&D cen­ter in Kendall Square — which will al­so be Alex­ion's new HQ

Now that Pas­cal So­ri­ot has put the fin­ish­ing touch­es on As­traZeneca’s big R&D hub and head­quar­ters in Cam­bridge, UK, his sights are set on the oth­er Cam­bridge.

The phar­ma gi­ant will open a new, cus­tom-built space in Kendall Square, the beat­ing heart of the Cam­bridge, MA biotech scene, bring­ing to­geth­er 1,500 R&D, com­mer­cial and cor­po­rate staffers.

As well as a strate­gic R&D cen­ter, the site — which will span more than 70,000 square feet with room for fu­ture ex­pan­sion — will serve as the new cor­po­rate head­quar­ters for Alex­ion, which is now As­traZeneca’s rare dis­ease-fo­cused sub­sidiary fol­low­ing a $39 bil­lion buy­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER